2Wolf PA,Abbolt RD,Kannel WB.Atrial fibrillation as an independent risk factor for stroke:the Framingham Study[J].Stroke,1991,22(8):983-988.
3Benjamin EJ,Wolf PA, d'Agostino RB, et al. Impact of atrial fibrillation on the fist of death: the Framingham heart study[J]. Circulation, 1998,98(10) :946-952.
4Frustaci A,Chimenti C,Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation[J].Circulation, 1997,96 (4):1180-1184.
5Bruins P, Vehhuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery:postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia[J].Circulation, 1997,96 (10) : 3542-3548.
6Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation [J].Criculation, 2001,104(24):2886-2891.
7Dernellis J, Panaretou M. C-reactive protein and paroxysmal atrial fibrillation. evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation[J]. ActaCardiol, 2001,56(6):375-380.
8Aviles RJ, Martin DO, Appenson-Hansen C, et al.Inflammatinn as a risk for atrial fibriltation[,J]. Circulation,2003,108(24):3006-3010.
9Psychari SN,Apostolou TS,Sinos L,et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation[J]. Am J Cardiol, 2005,95 (6) : 764-767.
10Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation [J ]. Eur Heart J, 2004, 25 (13):1100-1107.
3Shepherd J, Blarw GJ, Murphy MB, et al. Pravasiatin in elderly individuals at risk of vascular disease (PROSPER ) : a rand,)mised controlled trial[J]. Lancet ,2002,60 ( 9346 ) : 1623 - 1630.
4Austin PC, Mamdani MM. Impact of the pravaslatin or atorvastatin evaluation and infection therapy - thrombolysis in myocardial in - faretion 22/Reversal of atherosclerosis with aggressive lipid lowering trials on trends in intensive versus moderate statin therapy in ontario,Canada [J]. Circulation, 2005,12 ( 9 ) : 1296 - 1300.
5Nissen SE, Juzcu EM, Schoenhagen P, el al. Effect of intensive compared with moderate lipid - lowering therapy on progression of coronary atherosclerosis [J]. JAMA, 2004,291 : 1071 - 1080.
6Von Birgelen C.Hartmann M,Mintz GS,et al. Relation between progression and regression of atherosclerotic left main coronary artel7 disease and serun cholesterol levels as assessed with serial long - term ( 12 months) follow up intravascular ultrasound[J]. Circulation ,2003, 108:2757 - 2762.
7Williams K J, Feig JE, Fisher EA. Rapid regression of alheroselerosis: insights from the clinical and experimental literature [J]. Nat elin praet Cardiovasc Med ,2008,5 ( 2 ) :91 - 102.
8Young -xu Y ,Jabbour S, Gohlberg R, et al. Usefulness of stain drugs in protecting against atrial fibrillation in patients with Coronary artery disease[J]. Am J Cardiol, 2003,92 ( 12 ) : 1379 - 1383.
9Marin F, Pascual DA, Roldan V,et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting [J]. Am J Cardiol,2006,97 ( 1 ) :56 - 60.
10Patel R ,Nagueh SF,Tsybouleva N ,et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenie rabbit model of human hypertrophic cardiomyopathy [J]. Circulation,2001,104(3) :317 -324.
